Exonate’s principal scientist, Dr Jennifer Batson, to present at Pharmacology 2017

Dr Jennifer Batson will present ‘A Paradigm Shift in the Treatment of Retinal Vascular Diseases’ at Pharmacology 2017 on Tuesday 12 December 2017 Exonate is developing eye drops to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK – 11 December 2017: Exonate an early stage biotechnology company, today announces that its principal…

Exonate closes second successful funding round

Early stage biotechnology company targeting ophthalmology and potentially pain and cancer Funding to develop treatment for wet age-related macular degeneration (wet AMD) Cambridge, UK, Monday 5th October 2015 – Exonate, an early stage biotechnology company, today announced they have successfully closed their latest funding round including investment from the Angel CoFund. This brings the total…